Aditxt to Spin Off $150M Ignite Proteomics as Independent Public Company
ADTX•Aditxt agreed to separate its 100%-owned subsidiary Ignite Proteomics through a business combination agreement valuing Ignite at $150 million, with Pubco shares priced at $10.00 per share. The deal aims to unlock value while Aditxt remains a Nasdaq-listed company following recent top executive departures.
1. Agreement Terms
Aditxt and a strategic counterparty signed a definitive business combination agreement that values Ignite Proteomics at $150 million. Shareholders of Ignite are expected to receive newly issued shares of the newly formed public holding company, Pubco, based on a reference price of $10.00 per share.
2. Value Unlock and Spin-off
The transaction is designed to unlock value in Aditxt’s 100%-owned subsidiary by providing Ignite with standalone access to capital and market visibility. As an independent public company, Ignite can focus on accelerating commercialization, expanding clinical evidence generation and pursuing broader adoption of its functional proteomics platform in oncology.
3. Executive Departures
In the weeks preceding the announcement, several senior leaders resigned, including CEO Amro Albanna, COO Rowena Albanna, director Shahrokh Shabahang, Chief People Officer Christopher Porcelli and Non-Executive Chairman Brian Brady. These departures have raised questions about leadership continuity as Aditxt transitions through the spin-off process.
4. Next Steps and Timeline
Upon closing the transaction, Ignite will begin trading under Pubco, while Aditxt continues operating on Nasdaq. The companies have not provided a definitive closing date, but both intend to finalize the separation swiftly to realize the intended strategic and financial benefits.
